BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21087818)

  • 21. De novo CpG island methylation in human cancer cells.
    Jair KW; Bachman KE; Suzuki H; Ting AH; Rhee I; Yen RW; Baylin SB; Schuebel KE
    Cancer Res; 2006 Jan; 66(2):682-92. PubMed ID: 16423997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma.
    Hibi K; Taguchi M; Nakayama H; Takase T; Kasai Y; Ito K; Akiyama S; Nakao A
    Clin Cancer Res; 2001 Oct; 7(10):3135-8. PubMed ID: 11595706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients.
    Harden SV; Tokumaru Y; Westra WH; Goodman S; Ahrendt SA; Yang SC; Sidransky D
    Clin Cancer Res; 2003 Apr; 9(4):1370-5. PubMed ID: 12684406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
    Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
    Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered global methylation of DNA: an epigenetic difference in susceptibility for lung cancer is associated with its progression.
    Piyathilake CJ; Frost AR; Bell WC; Oelschlager D; Weiss H; Johanning GL; Niveleau A; Heimburger DC; Grizzle WE
    Hum Pathol; 2001 Aug; 32(8):856-62. PubMed ID: 11521231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA methyltransferase-mediated transcriptional silencing in malignant glioma: a combined whole-genome microarray and promoter array analysis.
    Foltz G; Yoon JG; Lee H; Ryken TC; Sibenaller Z; Ehrich M; Hood L; Madan A
    Oncogene; 2009 Jul; 28(29):2667-77. PubMed ID: 19465937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Correlation of aberrant methylation of MGMT gene to MTHFR C677T genetic polymorphisms in esophageal squamous cell carcinoma].
    Xue HC; Wang JM; Xu B; Guo GP; Hua ZL; Zhou Q; Zhu ZH; Ma ZK; Gao J
    Ai Zheng; 2008 Dec; 27(12):1256-62. PubMed ID: 19079989
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA methyltransferase 1 expression and promoter methylation of E-cadherin in mucoepidermoid carcinoma.
    Shieh YS; Shiah SG; Jeng HH; Lee HS; Wu CW; Chang LC
    Cancer; 2005 Sep; 104(5):1013-21. PubMed ID: 15999364
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations of DNA methylation and clinicopathological diversity of human cancers.
    Kanai Y
    Pathol Int; 2008 Sep; 58(9):544-58. PubMed ID: 18801069
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aberrant methylation: common in thymic carcinomas, rare in thymomas.
    Suzuki M; Chen H; Shigematsu H; Ando S; Iida T; Nakajima T; Fujisawa T; Kimura H
    Oncol Rep; 2005 Dec; 14(6):1621-4. PubMed ID: 16273266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells.
    Lin RK; Hsu CH; Wang YC
    Anticancer Drugs; 2007 Nov; 18(10):1157-64. PubMed ID: 17893516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Epigenome and cancer: new possibilities of cancer prevention and therapy?].
    Paluszczak J; Baer-Dubowska W
    Postepy Biochem; 2005; 51(3):244-50. PubMed ID: 16381168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aberrant promoter hypermethylation in biliary tract carcinoma.
    Kohya N; Koga Y; Kitajima Y; Miyazaki K
    J Hepatobiliary Pancreat Surg; 2006; 13(4):296-305. PubMed ID: 16858540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant methylation of tumour-related genes in thymic epithelial tumours.
    Hirose Y; Kondo K; Takizawa H; Nagao T; Nakagawa Y; Fujino H; Toba H; Kenzaki K; Sakiyama S; Tangoku A
    Lung Cancer; 2009 May; 64(2):155-9. PubMed ID: 18778870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An essential role for DNA methyltransferase 3a in melanoma tumorigenesis.
    Deng T; Kuang Y; Wang L; Li J; Wang Z; Fei J
    Biochem Biophys Res Commun; 2009 Sep; 387(3):611-6. PubMed ID: 19632198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma.
    Park HJ; Yu E; Shim YH
    Cancer Lett; 2006 Feb; 233(2):271-8. PubMed ID: 15885882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
    Long C; Yin B; Lu Q; Zhou X; Hu J; Yang Y; Yu F; Yuan Y
    Cancer Invest; 2007 Dec; 25(8):685-90. PubMed ID: 18058463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stalling of DNA methyltransferase in chromosome stability and chromosome remodelling (Review).
    Smith SS
    Int J Mol Med; 1998 Jan; 1(1):147-56. PubMed ID: 9852213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Clin Cancer Res; 2003 Apr; 9(4):1441-5. PubMed ID: 12684417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.